title: Nilotinib-Induced Keratosis Pilaris.
abstract: Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor (TKI) that is approved for the treatment of imatinib-resistant chronic myeloid leukaemia expressing the Bcr-Abl mutation. Cutaneous adverse drug reactions occur more frequently in patients using this medication. We present a case of nilotinib-induced keratosis pilaris that did not have accompanying symptoms of alopecia or pruritus. Greater recognition of this association is needed so that appropriate treatment can be instituted to ensure a good oncologic outcome.
authors.affiliation: Division of Dermatology, Department of Medicine, National University Health Systems, Singapore, Singapore.
authors.forename: Wai Mun Sean
authors.initials: WM
authors.lastname: Leong
authors.affiliation: Division of Dermatology, Department of Medicine, National University Health Systems, Singapore, Singapore.
authors.forename: Chen Wee Derrick
authors.initials: CW
authors.lastname: Aw
keywords: Bcr-Abl tyrosine kinase inhibitors; Chronic myeloid leukaemia; Keratosis pilaris